ArticleScientific reports2025
Identification of key genes predicting the efficacy of mepolizumab in the treatment of severe eosinophilic asthma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe eosinophilic asthma is a treatment-resistant subtype that remains poorly controlled with conventional therapies. According to the latest European Respiratory Society (ERS) guidelines, anti-interleukin-5 (anti-IL-5) biologics such as mepolizumab are recommended for these patients. However, not all individuals respond favorably to mepolizumab. This study aimed to identify gene expression biomarkers predictive of therapeutic response to mepolizumab, facilitating early identification of likely responders. Transcriptomic data (GSE274410) were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) between responder and non-responder groups were identified. Functional enrichment was conducted using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) gene sets via gene set enrichment analysis (GSEA). Protein-protein interaction (PPI) networks were constructed using the STRING database, and hub genes were identified with the cytoHubba plugin in Cytoscape. Box plots were used to visualize gene expression patterns. FOS and CXCL3 were significantly downregulated in the responder group. Their predictive value was further assessed using receiver operating characteristic (ROC) curve analysis. These findings suggest that FOS and CXCL3 may serve as promising biomarkers for predicting response to mepolizumab and may aid in stratifying patients with severe eosinophilic asthma for individualized biologic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.